We are live on ! Find out more

2,392 hedge funds and large institutions have $173B invested in Pfizer in 2019 Q1 according to their latest regulatory filings, with 132 funds opening new positions, 906 increasing their positions, 1,113 reducing their positions, and 111 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more first-time investments, than exits

New positions opened: 132 | Existing positions closed: 111

19% more call options, than puts

Call options by funds: $1.53B | Put options by funds: $1.29B

1.62% more ownership

Funds ownership: 75.91%77.53% (+1.6%)

0% less funds holding

Funds holding: 2,4042,392 (-12)

4% less capital invested

Capital invested by funds: $180B → $173B (-$6.79B)

19% less repeat investments, than reductions

Existing positions increased: 906 | Existing positions reduced: 1,113

38% less funds holding in top 10

Funds holding in top 10: 328202 (-126)

Holders
2,392
Holders Change
-12
Holders Change %
-0.5%
% of All Funds
51.76%
Holding in Top 10
202
Holding in Top 10 Change
-126
Holding in Top 10 Change %
-38.41%
% of All Funds
4.37%
New
132
Increased
906
Reduced
1,113
Closed
111
Calls
$1.53B
Puts
$1.29B
Net Calls
+$241M
Net Calls Change
+$316M
Name Holding Trade Value Shares
Change
Change in
Stake
BFA
876
Brendel Financial Advisors
New Hampshire
$4.26M -$65.9K -1,645 -2%
WPP
877
Whalerock Point Partners
Rhode Island
$4.25M +$321K +8,010 +8%
TRCT
878
Tower Research Capital (TRC)
New York
$4.25M -$634K -15,838 -13%
ACM
879
Advent Capital Management
New York
$4.25M +$3.59M +89,590 +567%
ACP
880
Ashfield Capital Partners
California
$4.25M -$240 -6 -0%
VCM
881
Vigilant Capital Management
Maine
$4.24M -$120K -3,001 -3%
GCM
882
Gladius Capital Management
Illinois
$4.23M -$2.89M -72,237 -41%
MCM
883
McMillion Capital Management
North Carolina
$4.23M +$81.1K +2,025 +2%
RIM
884
Rampart Investment Management
Connecticut
$4.23M +$1.58M +39,356 +60%
GHAM
885
Gilman Hill Asset Management
Connecticut
$4.21M -$695K -17,351 -14%
HR
886
Howe & Rusling
New York
$4.21M +$964K +24,074 +30%
TAM
887
Tiverton Asset Management
Delaware
$4.2M +$4.18M +104,318 New
KC
888
Knuff & Co
California
$4.18M +$29.5K +737 +0.7%
TF
889
Tompkins Financial
New York
$4.18M +$88.7K +2,215 +2%
TRIM
890
Thompson Rubinstein Investment Management
Oregon
$4.17M +$8.45K +211 +0.2%
AIC
891
Argus Investors Counsel
New York
$4.15M -$155K -3,879 -4%
APA
892
American Portfolios Advisors
New York
$4.13M -$238K -5,946 -5%
FFWA
893
FRG Family Wealth Advisors
Washington
$4.13M +$56.5K +1,412 +1%
HKIM
894
Hayek Kallen Investment Management
Alabama
$4.12M +$33.6K +840 +0.8%
ECM
895
ETrade Capital Management
Virginia
$4.12M -$4.75M -118,487 -54%
HSA
896
HBK Sorce Advisory
Pennsylvania
$4.11M +$29.8K +745 +0.7%
SHCM
897
Stokes & Hubbell Capital Management
Louisiana
$4.11M -$76.7K -1,914 -2%
BAM
898
Belpointe Asset Management
Nevada
$4.11M +$175K +4,379 +4%
BMO
899
Beck Mack & Oliver
New York
$4.1M
PS
900
Pensionfund Sabic
Netherlands
$4.1M -$929K -23,188 -19%

PFE Hedge Fund Activity: Q1 2019 in Review

2,392 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q1 2019, worth a combined $173B — down 3.8% from $180B a quarter earlier.

Buyers outnumbered sellers: 132 funds opened new PFE positions and 111 closed out — a net gain of 21 holders — while 906 added to existing stakes and 1,113 trimmed.

The largest buyer was Capital World Investors, adding an estimated $967M. The largest seller was BlackRock, cutting an estimated $715M.

  • 2,392 institutional investors held Pfizer (PFE) as of Q1 2019, down from 2,404 in Q4 2018.
  • Funds reported $173B of Pfizer stock for Q1 2019, down 3.8% quarter-over-quarter.
  • 132 funds opened new Pfizer positions in Q1 2019 and 111 closed out, a net change of +21 holders.
  • The largest Pfizer buyer in Q1 2019 was Capital World Investors, an estimated $967M added.
  • The largest Pfizer seller in Q1 2019 was BlackRock, an estimated $715M sold.

Based on aggregated 13F filings for Q1 2019.